Bristol Myers Squibb (BMY, Financial) has revealed disappointing outcomes from its Phase 3 ODYSSEY-HCM trial, which assessed the efficacy of Camzyos for adults with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM). This trial aimed to evaluate improvements from baseline to Week 48 in specific health measures, including the Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score and peak oxygen consumption, as compared to a placebo. Unfortunately, the trial did not achieve these dual primary endpoints.
Despite the setback, the company emphasized that no new safety concerns arose from this study. Roland Chen, MD, highlighted the trial’s contribution to understanding non-obstructive HCM, stressing the continued need for treatments in this area. He reaffirmed that these findings do not alter the positive benefit-risk profile of Camzyos as demonstrated in trials and real-world data for obstructive HCM.
This development marks the first Phase 3 clinical trial data for a cardiac myosin inhibitor in the context of non-obstructive HCM, providing valuable insights for future research and therapeutic strategies.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.